Skip to main content
. 2014 Sep 11;2014(9):CD010678. doi: 10.1002/14651858.CD010678.pub2
Methods Trial design: Open label RCT
Trial dates: January 1992 to June 1994
Participants Number: 183 children enrolled (age range not stated)
Inclusion criteria: Children with asexual forms of P. falciparum detected in a peripheral blood smear, and a Blantyre Coma Score ≤ 2, and if no other cause of fever or altered consciousness could be discovered.
Exclusion criteria: None stated
Interventions 1. Intramuscular artemether
  • Loading dose of 3.2 mg/kg on admission

  • Followed by 1.6 mg/kg once daily. A minimum of three doses were given.

  • Then oral sulphadoxine‐pyrimethamine (approximately 25 mg/kg sulphadoxine and 1.25 mg/kg pyrimethamine) if parasitaemia had cleared and the patient was fully conscious.


2. Intravenous quinine
  • Loading dose of 20 mg/kg infused over four hours.

  • Followed by 10 mg/kg infused over two hours at eight hour intervals. After a minimum of three intravenous quinine doses oral quinine given in 10 mg/kg doses at eight hour intervals if the patient was able to drink

  • Then oral sulphadoxine‐pyrimethamine (same as above).

Outcomes Outcomes included in the review:
  1. Death

  2. Coma resolution time

  3. Neurological sequelae

  4. Fever clearance time

  5. Parasite clearance time


Outcomes not included in the review:
  1. Recurrent parasitaemia

  2. Reticulocyte response

Notes Location: Paediatric ward at the Queen Elizabeth Central Hospital, Malawi
Transmission: Unknown
Funding: UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Block randomization.
Allocation concealment (selection bias) Low risk "Randomized treatment assignments were prepared in blocks of ten by the sponsoring agency.Following initial stabilization, diagnosis and examination, a sealed envelope containing the treatment group was opened, and the patient was allocated to treatment".
Blinding (performance bias and detection bias) Objective outcome: Death Low risk An open‐label trial is unlikely to bias an objective outcome like death.
Blinding (performance bias and detection bias) Subjective outcomes: Others High risk An open‐label trial.
Incomplete outcome data (attrition bias) All outcomes High risk Differential proportion of withdrawals from both arms (13% versus 8%).
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No other bias identified.